BXRXQ (Baudax Bio) Return-on-Tangible-Asset: -93.96% (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BXRXQ Baudax Bio Inc BXRXQ
12 GF Score
Price $0.00
View Full Analysis

What is Baudax Bio Return-on-Tangible-Asset?

Baudax Bio BXRXQ -99.00% 12 Return-on-Tangible-Asset is -93.96% as of Sep. 2023. GuruFocus rates BXRXQ with a GF Score™ of 12/100.

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Baudax Bio's annualized Net Income for the quarter that ended in Sep. 2023 was $-7.74 Mil. Baudax Bio's average total tangible assets for the quarter that ended in Sep. 2023 was $8.23 Mil. Therefore, Baudax Bio's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2023 was -93.96%.

The historical rank and industry rank for Baudax Bio's Return-on-Tangible-Asset or its related term are showing as below:

BXRXQ's Return-on-Tangible-Asset is not ranked *
in the Biotechnology industry.
Industry Median: -35.71
* Ranked among companies with meaningful Return-on-Tangible-Asset only.

Baudax Bio  (OTCPK:BXRXQ) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Baudax Bio Return-on-Tangible-Asset Related Terms


Baudax Bio Return-on-Tangible-Asset Historical Data

* Premium members only.

The historical data trend for Baudax Bio's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Baudax Bio Return-on-Tangible-Asset Chart

Baudax Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Return-on-Tangible-Asset
Get a 7-Day Free Trial -1,373.10 -202.33 -223.70 -55.05 -314.61

Baudax Bio Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -737.09 -347.58 710.36 -436.46 -93.96

BXRXQ vs INM, NBRVF, SPRC: Return-on-Tangible-Asset Comparison

For the Biotechnology subindustry, Baudax Bio's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Baudax Bio Return-on-Tangible-Asset vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Baudax Bio's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Baudax Bio's Return-on-Tangible-Asset falls into.


BXRXQ
12GF Score
Baudax Bio Inc BXRXQ
Return-on-Tangible-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Baudax Bio Return-on-Tangible-Asset Calculation

Baudax Bio's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2022 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2022 )  (A: Dec. 2021 )(A: Dec. 2022 )
=-58.795/( (29.472+7.905)/ 2 )
=-58.795/18.6885
=-314.61 %

Baudax Bio's annualized Return-on-Tangible-Asset for the quarter that ended in Sep. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Sep. 2023 )  (Q: Jun. 2023 )(Q: Sep. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Sep. 2023 )  (Q: Jun. 2023 )(Q: Sep. 2023 )
=-7.736/( (8.58+7.886)/ 2 )
=-7.736/8.233
=-93.96 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Sep. 2023) net income data.

What does a Return-on-Tangible-Asset of -93.96% mean?
Baudax Bio (BXRXQ) has a Return-on-Tangible-Asset of -93.96% as of Sep. 2023. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Baudax Bio and its competitors.
Is Baudax Bio's Return-on-Tangible-Asset too high?
Baudax Bio's current Return-on-Tangible-Asset is -93.96%. Overall, Baudax Bio has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Baudax Bio's Return-on-Tangible-Asset compare to INM and NBRVF?
Baudax Bio's Return-on-Tangible-Asset of -93.96% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Baudax Bio and its competitors. Baudax Bio's current Return-on-Tangible-Asset is -93.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Baudax Bio stock overvalued right now?
Baudax Bio (BXRXQ) has a current Return-on-Tangible-Asset of -93.96%. The current Return-on-Tangible-Asset is -93.96%. Baudax Bio's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Baudax Bio (BXRXQ), the current Return-on-Tangible-Asset is -93.96% as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Baudax Bio Business Description

Address 490 Lapp Road, Malvern, PA, USA, 19355
Baudax Bio Inc is a Pharmaceutical company. The company develops and commercialize products for hospital and related acute care settings. Its products are in pipeline which includes two novel neuromuscular blocking agents, or NMBAs and a dedicated reversal agent.
12GF Score

Get the complete analysis for BXRXQ

Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price